GSK Pays $500M Upfront in $12B Deal with Hengrui Pharma

Published on LinkedIn via Spencer Knight

GSK has entered a $12 billion licensing deal with China’s Hengrui Pharma, paying $500 million upfront for HRS‑9821, a promising PDE3/4 inhibitor for COPD with bronchodilatory and anti-inflammatory properties. Beyond the lead asset, GSK also secured exclusive options on 11 early-stage drug candidates across respiratory, immunology, inflammation, and oncology. This deal marks a continued strategic push by GSK into Chinese innovation just 18 months after acquiring Aiolos Bio, another Hengrui spinout.

Read the full article on LinkedIn:

👉 GSK’s $500M bet on Chinese respiratory and immunology assets

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.